Epic Bio, is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.
Total raised: $68M
Founded date: 2018
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.03.2025 | Series B | $68M | - |
Mentions in press and media 3
| Date | Title | Description |
| 31.03.2025 | Epicrispr Biotechnologies: A New Dawn in Genetic Therapy | Epicrispr Biotechnologies is making waves in the biotechnology sector. The company recently secured $68 million in Series B funding. This financial boost is a beacon of hope for patients suffering from facioscapulohumeral muscular dystrophy... |
| 30.03.2025 | Epicrispr Biotechnologies: $68 Million (Series B) Raised For Developing Curative Therapies | Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, announced it has secured $68 million in the first close of its Series B financing. The proceeds from the funding will support the clinical developm... |
| 26.03.2025 | Epicrispr Biotechnologies Raises $68M in Series B Funding | Epicrispr Biotechnologies, a South San Francisco, CA-based biotechnology company focused on developing curative therapies, raised $68m in the first close of its Series B financing. The round was led by Ally Bridge Group, with participation ... |